TXMD
NASDAQ · Pharmaceuticals
Therapeuticsmd Inc
$2.34
+0.05 (+2.18%)
Financial Highlights (FY 2026)
Revenue
1.80M
Net Income
-2,228,506
Gross Margin
100.0%
Profit Margin
-123.9%
Rev Growth
-11.8%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 47.0% | 47.0% |
| Operating Margin | -270.3% | -243.3% | 33.6% | 32.8% |
| Profit Margin | -123.9% | -117.7% | 26.2% | 22.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.80M | 2.04M | 4.86M | 6.01M |
| Gross Profit | 1.80M | 2.04M | 2.28M | 2.83M |
| Operating Income | -4,864,153 | -4,965,673 | 1.63M | 1.97M |
| Net Income | -2,228,506 | -2,275,017 | 1.27M | 1.34M |
| Gross Margin | 100.0% | 100.0% | 47.0% | 47.0% |
| Operating Margin | -270.3% | -243.3% | 33.6% | 32.8% |
| Profit Margin | -123.9% | -117.7% | 26.2% | 22.4% |
| Rev Growth | -11.8% | -11.8% | +8.5% | +15.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 6.73M | 8.04M |
| Total Equity | — | — | 11.85M | 11.59M |
| D/E Ratio | — | — | 0.57 | 0.69 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -2,012,844 | -2,169,012 | 2.17M | 2.73M |
| Free Cash Flow | — | — | 1.08M | 1.44M |